Indicated for: iron overload
Route of administration: oral
Substance: deferasirox (chelating agent)
ATC: V03AC03 (Various | All other therapeutic products | Iron chelating agents)
Deferasirox is an iron chelator used for the treatment of chronic iron overload in patients with frequent blood transfusions, such as those with major thalassemia. It works by binding excess iron, facilitating its elimination through feces.
The medication is taken orally, usually once daily, with the dose adjusted based on the body's iron levels and the patient's weight. Common side effects include nausea, diarrhea, abdominal pain, and elevated liver enzymes.
Deferasirox is contraindicated in patients with severe renal impairment, hepatic failure, or hypersensitivity to the active substance. Its use also requires regular monitoring of renal and hepatic function.
This medication is an effective option for managing iron overload, helping to prevent complications associated with this condition.
G10 (C1) - Leukemias, lymphomas and bone marrow aplasia, tumors
Price
Copayment
Patient
2171.72 RON
457.74 RON
1713.98 RON
GX (C1) - GENERIC (used in compensation list, C1, for another diagnosis)
Price
Copayment
Patient
2171.72 RON
457.74 RON
1713.98 RON
NHP 6.1 (C2) - Hemophilia and thalassemia
Price
Copayment
Patient
2171.72 RON
457.74 RON
1713.98 RON